Dominari Holdings Inc. (NASDAQ:DOMH) Sees Significant Growth in Short Interest

Dominari Holdings Inc. (NASDAQ:DOMH) saw a significant growth in short interest during the month of February. As of February 15th, there was short interest totalling 952,800 shares, a growth of 232.0% from the January 31st total of 287,000 shares. Approximately 30.6% of the shares of the company are short sold. Based on an average daily trading volume, of 1,480,000 shares, the days-to-cover ratio is presently 0.6 days.

Institutional Trading of Dominari

A hedge fund recently raised its stake in Dominari stock. Renaissance Technologies LLC lifted its holdings in Dominari Holdings Inc. (NASDAQ:DOMH) by 20.0% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 56,326 shares of the company’s stock after purchasing an additional 9,400 shares during the quarter. Renaissance Technologies LLC owned 0.89% of Dominari worth $55,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 42.48% of the company’s stock.

Dominari Stock Performance

Shares of Dominari stock traded down $0.20 during trading on Friday, hitting $7.57. 180,790 shares of the stock were exchanged, compared to its average volume of 2,456,141. Dominari has a 12 month low of $0.83 and a 12 month high of $13.58. The stock’s fifty day moving average is $3.81 and its 200 day moving average is $2.44. The stock has a market cap of $47.96 million, a PE ratio of -1.96 and a beta of 1.25.

Dominari Announces Dividend

The firm also recently disclosed a dividend, which will be paid on Monday, March 3rd. Stockholders of record on Monday, February 24th will be given a dividend of $0.32 per share. The ex-dividend date of this dividend is Monday, February 24th.

Dominari Company Profile

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.